✦ LIBER ✦

Structure−Activity Relationship Studies of Novel Benzophenones Leading to the Discovery of a Potent, Next Generation HIV Nonnucleoside Reverse Transcriptase Inhibitor

✍ Scribed by Romines, Karen R.; Freeman, George A.; Schaller, Lee T.; Cowan, Jill R.; Gonzales, Steve S.; Tidwell, Jeffrey H.; Andrews, Clarence W.; Stammers, David K.; Hazen, Richard J.; Ferris, Robert G.

Book ID: 115483126
Publisher: American Chemical Society
Year: 2006
Tongue: English
Weight: 203 KB
Volume: 49
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm050670l

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toward the Discovery of Novel Anti-HIV D

Toward the Discovery of Novel Anti-HIV Drugs. Second-Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti-HIV Activity: Synthesis, Structure–Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation

✍ Dr. Giovanni Maga; Dr. Federico Falchi; Dr. Marco Radi; Dr. Lorenzo Botta; Dr. G 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 924 KB

ChemInform Abstract: Structure—Activity

ChemInform Abstract: Structure—Activity Relationship Study on a Novel Series of Cyclopentane-Containing Macrocyclic Inhibitors of the Hepatitis C Virus NS3/4H Protease Leading to the Discovery of TMC435350.

✍ Pierre Raboisson; et al. et al. 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 20 KB 👁 1 views

2-Aminothiazole as a Novel Kinase Inhibi

2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor

✍ Das, Jagabandhu; Chen, Ping; Norris, Derek; Padmanabha, Ramesh; Lin, James; Moqu 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 396 KB

43 The discovery and general SAR studies

43 The discovery and general SAR studies of a novel class of potent non-nucleoside reverse transcriptase inhibitors: R. J. Ternansky1, J. M. Morin, Jr.1, C. Lopez1, C. J. Paget, Jr.1, F. W. Bell1, A. S. Cantrell1, S. R. Jaskunas1, C. L. Jordan1, M. D. Kinnick1, J. A. Palkowitz1, C. A. Parrish1, P. Pranc1, R. T. Vasileff1, S. J. West1, M. Hogberg2, P. Lind2, R. Noreen2, C. Sahlberg2, X.-X. Zhou2, L. Vrang2, C. Rydergard2, C. Ahgren2, B. Oberg2, and N. G. Johansson2. 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Medivir AB, Huddinge, Sweden

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 50 KB